Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied
in the past decade, but effective approaches to prevent and treat this disease are limited …

Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …

Mitochondrial dysfunction has been regarded as a hallmark of diabetic cardiomyopathy. In
addition to their canonical metabolic actions, mitochondria influence various other aspects of …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Abstract Aims Sodium-glucose-cotransporter-2 inhibitors showed favourable cardiovascular
outcomes, but the underlying mechanisms are still elusive. This study investigated the …

Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic
interventions to prevent or treat these disorders are sparse. Ketones carry a negative clinical …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

In myocardial ischemia/reperfusion injury (MIRI), moderate mitophagy is a protective or
adaptive mechanism because of clearing defective mitochondria accumulates during MIRI …

Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF)
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …